Adaptive Biotechnologies Valuation

ADPT Stock

USD 8.29 0.05 0.61%

What would the acquisition value of Adaptive Biotechnologies be today? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Adaptive Biotechnologies, is its stock price multiplied by the total number of shares outstanding, calculating Adaptive Biotechnologies' enterprise value requires a different approach. It uses Adaptive Biotechnologies' balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.

Adaptive Biotechnologies Enterprise Value is comparatively stable at the moment as compared to the past year. Adaptive Biotechnologies reported Enterprise Value of 1.11 Billion in 2022. Tangible Asset Value is likely to gain to about 743.9 M in 2023, whereas Free Cash Flow is likely to drop (205.6 M) in 2023.

Adaptive Biotechnologies shows a prevailing Real Value of $9.72 per share. The current price of the firm is $8.29. At this time, the firm appears to be undervalued. Our model approximates the value of Adaptive Biotechnologies from analyzing the firm fundamentals such as return on equity of (0.38) %, and Profit Margin of (1.08) % as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor acquiring undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will blend.

Adaptive Biotechnologies Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Adaptive Biotechnologies's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.

Adaptive Most Recent Valuation Data

Beta

1.1733

Change Receivables

-22.6 M

Fiscal Year End

December

Property Plant And Equipment Net

164.2 M

Enterprise Value

789.4 M

Undervalued

Today 8.29

Please note that Adaptive Biotechnologies' price fluctuation is slightly risky at this time. Calculation of the real value of Adaptive Biotechnologies is based on 3 months time horizon. Increasing Adaptive Biotechnologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.

Buy or Sell Advice Valuation Matrix

Our valuation method for Adaptive Biotechnologies Corp is useful when determining the fair value of the Adaptive stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Adaptive Biotechnologies. Since Adaptive Biotechnologies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Adaptive Stock. However, Adaptive Biotechnologies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.

5.45

Downside

9.72

Real Value

Target Odds

Above Odds

Below Odds

13.99

Upside

Estimating the potential upside or downside of Adaptive Biotechnologies Corp helps investors to forecast how Adaptive stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Adaptive Biotechnologies more accurately as focusing exclusively on Adaptive Biotechnologies' fundamentals will not take into account other important factors:

Bollinger

Band Projection (param)

Lower	Middle Band	Upper
7.76	8.34	8.93

Details

Hype

Prediction

Low	Estimated Value	High
4.17	8.44	12.71

Details

Naive

Forecast

Low	Next Value	High
4.45	8.73	13.00

Details

8 Analysts

Consensus

Low	Target Price	High
10.00	13.33	15.00

Details

Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Adaptive Biotechnologies' intrinsic value based on its ongoing forecasts of Adaptive Biotechnologies' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Adaptive Biotechnologies' closest peers. When choosing an evaluation method for Adaptive Biotechnologies, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.

Adaptive Biotechnologies Investments

440.05 Million

Adaptive Valuation Drivers Correlation

Many accounts on the financial statements of Adaptive Biotechnologies are highly interrelated and sometimes correlated. Consequently, when conducting Adaptive's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Adaptive

Click cells to compare fundamentals

Adaptive Valuation Trend

Knowing Adaptive Biotechnologies' actual value is paramount for traders to make sound investment determinations. Adaptive Biotechnologies' real value is not only important for the investor to make better decisions but also for a more accurate overall view of Adaptive Biotechnologies' financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Adaptive Biotechnologies' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.

Adaptive Market Cap

Adaptive Biotechnologies Corp is number one stock in market capitalization category among related companies. Market capitalization of Health Care industry is presently estimated at about 1.8 Trillion. Adaptive Biotechnologies adds roughly 1.18 Billion in market capitalization claiming only tiny portion of equities under Health Care industry.

Capitalization Total debt Valuation Workforce Revenue

Adaptive Biotechnologies Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Adaptive Biotechnologies's current stock value. Our valuation model uses many indicators to compare Adaptive Biotechnologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Adaptive Biotechnologies competition to find correlations between indicators driving Adaptive Biotechnologies's intrinsic value. More Info.

Adaptive Biotechnologies Corp is number one stock in price to earning category among related companies. It is number one stock in price to sales category among related companies fabricating about 26.55 of Price to Sales per Price to Earning. Price to Sales Ratio is likely to gain to 6.03 in 2023. Comparative valuation analysis is a catch-all model that can be used if you cannot value Adaptive Biotechnologies by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Adaptive Biotechnologies' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Adaptive Biotechnologies' earnings, one of the primary drivers of an investment's value.

Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Adaptive Biotechnologies' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Adaptive Biotechnologies and how it compares across the competition.

About Adaptive Biotechnologies Valuation

The stock valuation mechanism determines the current worth of Adaptive Biotechnologies Corp on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Adaptive Biotechnologies Corp. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Adaptive Biotechnologies based exclusively on its fundamental and basic technical indicators. By analyzing Adaptive Biotechnologies's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Adaptive Biotechnologies's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Adaptive Biotechnologies. We calculate exposure to Adaptive Biotechnologies's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Adaptive Biotechnologies's related companies.

Fiscal Year End

December

Industry

Biotechnology

Concentration

Life Sciences Tools & Services

Full Time Employees

790

Service Category

Life Sciences Tools & Services

	Last Reported	Projected for 2023
Gross Profit	127.4 M	108.5 M
Profit Margin	(1.08)	(1.16)

Adaptive Biotechnologies Quarterly Enterprise Value

1.11 Billion

8 Steps to conduct Adaptive Biotechnologies' Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Adaptive Biotechnologies' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Adaptive Biotechnologies' valuation analysis, follow these 8 steps:

Gather financial information: Obtain Adaptive Biotechnologies' financial statements, including balance sheets, income statements, and cash flow statements.
Determine Adaptive Biotechnologies' revenue streams: Identify Adaptive Biotechnologies' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
Analyze market data: Research Adaptive Biotechnologies' industry and market trends, including the size of the market, growth rate, and competition.
Establish Adaptive Biotechnologies' growth potential: Evaluate Adaptive Biotechnologies' management, business model, and growth potential.
Determine Adaptive Biotechnologies' financial performance: Analyze its financial statements to assess its historical performance and future potential.
Choose a valuation method: Consider the company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Adaptive Biotechnologies' estimated value.
Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.

Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.

Adaptive Biotechnologies Growth Indicators

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Adaptive Biotechnologies does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.

	Common Stock Shares Outstanding	142.5 M
	Retained Earnings	-919.1 M
	Retained Earnings Total Equity	-919.1 M

Adaptive Biotechnologies Current Valuation Indicators

Valuation refers to the process of determining the present value of Adaptive Biotechnologies Corp and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Adaptive we look at many different elements of the entity such as Adaptive's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Adaptive Biotechnologies' valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Adaptive Biotechnologies' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.

	Book Value per Share
	Enterprise Value over EBIT
	Enterprise Value over EBITDA
	Price to Book Value

Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Adaptive Biotechnologies, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Adaptive Biotechnologies' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Adaptive Biotechnologies' worth.

Check out Trending Equities. For more information on how to buy Adaptive Stock please use our How to Invest in Adaptive Biotechnologies guide. You can also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for analysis

When running Adaptive Biotechnologies price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.

	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Bond Directory Find actively traded corporate debentures issued by US companies
	Fund Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Stock Screener Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format

Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.54)

Revenue Per Share

1.3

Quarterly Revenue Growth

0.455

Return On Assets

(0.14)

Return On Equity

(0.38)

The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine Adaptive Biotechnologies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2023 Macroaxis LLC

	Net Income Per Employee	Revenue Per Employee	Average Assets	EBITDA	Earnings before Tax	Average Equity	Enterprise Value	Free Cash Flow	Invested Capital
Net Income Per Employee		0.55	0.52	-0.48	-0.47	0.52	-0.01	-0.21	0.53
Revenue Per Employee	0.55		-0.03	0.17	0.2	-0.02	0.54	0.24	-0.03
Average Assets	0.52	-0.03		-0.96	-0.95	1.0	0.04	-0.64	0.96
Earnings Before Interest Taxes and Depreciation Amortization EBITDA	-0.48	0.17	-0.96		1.0	-0.96	0.19	0.77	-0.89
Earnings before Tax	-0.47	0.2	-0.95	1.0		-0.94	0.24	0.77	-0.88
Average Equity	0.52	-0.02	1.0	-0.96	-0.94		0.04	-0.63	0.97
Enterprise Value	-0.01	0.54	0.04	0.19	0.24	0.04		0.11	0.03
Free Cash Flow	-0.21	0.24	-0.64	0.77	0.77	-0.63	0.11		-0.45
Invested Capital	0.53	-0.03	0.96	-0.89	-0.88	0.97	0.03	-0.45

Adaptive Biotechnologies Valuation

Adaptive Most Recent Valuation Data

Adaptive Biotechnologies Investments

440.05 Million

Adaptive Valuation Drivers Correlation

Adaptive Valuation Trend

Adaptive Market Cap

Adaptive Biotechnologies Valuation Ratios as Compared to Competition

About Adaptive Biotechnologies Valuation

Adaptive Biotechnologies Quarterly Enterprise Value

1.11 Billion

8 Steps to conduct Adaptive Biotechnologies' Valuation Analysis

Adaptive Biotechnologies Growth Indicators

Adaptive Biotechnologies Current Valuation Indicators

Complementary Tools for analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY